TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Microbot Medical ( (MBOT) ) just unveiled an update.
On October 16, 2025, Microbot Medical announced its participation in the Symposium on Clinical Interventional Oncology in Miami, marking the first commercial exhibition of its LIBERTY® Endovascular Robotic System following FDA clearance. The company has also completed the recruitment of its commercial leadership team to support the upcoming limited market release of the LIBERTY® System, positioning itself for growth in the endovascular care market.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a pioneering medical device company specializing in the development of advanced robotic technology for endovascular procedures. The company’s flagship product, the LIBERTY® Endovascular Robotic System, is a single-use, remotely operated robotic solution designed to enhance precision, efficiency, and safety in medical procedures.
Average Trading Volume: 4,355,178
Technical Sentiment Signal: Hold
Current Market Cap: $133M
See more data about MBOT stock on TipRanks’ Stock Analysis page.